Alto Neuroscience, Inc. (ANRO)
NYSE: ANRO · Real-Time Price · USD
25.46
-0.24 (-0.93%)
At close: Jul 8, 2026, 4:00 PM EDT
26.09
+0.63 (2.47%)
After-hours: Jul 8, 2026, 7:00 PM EDT
Alto Neuroscience Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
68
Market Cap
915.60M
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 210.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Phathom Pharmaceuticals | 204.89M |
| Geron | 196.12M |
| Zevra Therapeutics | 122.29M |
| Theravance Biopharma | 109.78M |
| CytomX Therapeutics | 35.54M |
| Inventiva | 7.94M |
| DBV Technologies | 5.74M |
ANRO News
- 22 days ago - Alto Neuroscience Transcript: 7th Annual HCW Neuro Perspectives Hybrid Conference - Transcripts
- 23 days ago - Alto Neuroscience highlights publication in Nature Medicine on Prime-Praxol - TheFly
- 23 days ago - Alto Neuroscience Highlights Nature Medicine Publication Demonstrating Significant Effects of Pramipexole on Anhedonia - Business Wire
- 23 days ago - Alto Neuroscience Slides: Corporate presentation - Filings
- 5 weeks ago - Alto Neuroscience Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 5 weeks ago - Alto Neuroscience appoints Miller to Board of Directors - TheFly
- 5 weeks ago - Alto Neuroscience Appoints Karuna Therapeutics Founder Andrew Miller, Ph.D. to Board of Directors - Business Wire
- 6 weeks ago - Alto Neuroscience price target lowered to $33 from $35 at BofA - TheFly